PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerviewpress.com
R. Scott Wright, MD - When Statins Strike Out: Using PCSK9-Targeting Strategies to Achieve Lipid Goals and Reduce Cardiovascular Risks in Patients With Hyperlipidemia
Go online to PeerView.com/EEG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple professional societies have emphasized the importance of lowering LDL-C for the primary and secondary prevention of ASCVD and cardiovascular events. Though current guidelines recommend statins as the cornerstone of lipid-lowering therapies, many patients have insufficient response or intolerance to them and require non-statin therapies to achieve their individualized LDL-C goals. Enter PCSK9-targeting therapies! This CME activity shares current gaps in hyperlipidemia care, offers strategies for meeting these unmet needs, and presents the latest clinical data for PCSK9-targeting agents. An in-depth patient case example helps to illustrate the importance of screening and ASCVD risk assessment, how to initiate therapy with novel strategies, and best practices for improving hyperlipidemia management to help more patients achieve their goals. Upon completion of this activity, participants should be better able to: Incorporate evidence-based, guideline-compliant strategies into the management of hyperlipidemia to prevent primary and secondary cardiovascular events, especially in patients who are statin intolerant or already using the maximally tolerated statin dosage; Recognize the differences among PCSK9-targeting agents and other classes of lipid-lowering therapies for managing hyperlipidemia in individuals at high risk of ASCVD with regard to mechanisms of action, cardiovascular outcomes, and the latest clinical evidence; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for PCSK9-targeting therapies.